Newbioideas

Molecular and Therapeutic insights into Osteoclastogenesis and its associated disorders: Tumor suppressor ARF inhibits osteoporosis and bone metastasis


AMOUNT: $ 200

A study from theDepartment of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USAhas reported that“miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.”

This study was published in theJune 25, 2014Nature[I.F >35]byProf. Wan Y,Krzeszinskiand others fromtheDepartment of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.

On the foundation of this interesting finding,Dr L Boominathan,Director-cum-chief Scientist of GBMD,reports here that:Molecular and Therapeutic insights into Osteoclastogenesis and its associated disorders: Tumor suppressor ARF inhibits osteoporosis and bone metastasis.This study may suggest that ARF, by up regulating its target gene, it may suppress the expression of Tgif2. Together, this study suggests thatpharmacological formulations encompassing “ARF activators” can be used to inhibit osteoporosis and bone metastasis.

Idea Proposed/Formulatedby:Dr L Boominathan PhD

Terms & Conditionsapplyhttp://genomediscovery.org/registration/terms-and-conditions/

Courtesy:When you cite drop us a line atinfo@genomediscovery.org

Citation:Boominathan,Molecular and Therapeutic insights into Osteoclastogenesis and its associated disorders: Tumor suppressor ARFinhibits osteoporosis and bone metastasis, 25/July/2014, 06.03 am, Genome-2-Bio-MedicineDiscovery center(GBMD),http://genomediscovery.org

Web:http://genomediscovery.org

*Research cooperation

 

REGISTER

   

Dr.Boominathan PhD

Dr Boominathan was the first one in the world to propose a p73/p63-dependent cancer suppressor pathway (Supported by a legally valid Invention disclosure document certified by an advocate-2002/3)

Add comment

Most popular